Literature DB >> 12913830

Adverse events occurring after smallpox vaccination.

J Michael Lane1, Joel Goldstein.   

Abstract

We reviewed the literature on adverse events reported to occur after smallpox vaccination. Nearly one-half of the United States population is vaccinia-naïve and may be at risk for development of serious adverse events. We describe the clinical features of postvaccinial central nervous system disease, progressive vaccinia, eczema vaccinatum, accidental implantations, "generalized vaccinia," and the common erythematous and/or urticarial rashes. In the 1960s, death occurred approximately once in every million primary vaccinations, with fatalities resulting from progressive vaccinia, postvaccinial encephalitis, and eczema vaccinatum. Death in revaccinees occurred less commonly and almost entirely from progressive vaccinia. In today's population, death rates might be higher because of the increased prevalence of immune deficiency and atopic dermatitis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12913830     DOI: 10.1016/s1045-1870(03)00032-3

Source DB:  PubMed          Journal:  Semin Pediatr Infect Dis        ISSN: 1045-1870


  21 in total

1.  Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Authors:  Aklile Berhanu; Rebecca L Wilson; Dana L Kirkwood-Watts; David S King; Travis K Warren; Susan A Lund; Lindsay L Brown; Alex K Krupkin; Erin Vandermay; Will Weimers; Kady M Honeychurch; Douglas W Grosenbach; Kevin F Jones; Dennis E Hruby
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

2.  Smallpox inhibitor of complement enzymes (SPICE): dissecting functional sites and abrogating activity.

Authors:  M Kathryn Liszewski; Marilyn K Leung; Richard Hauhart; Celia J Fang; Paula Bertram; John P Atkinson
Journal:  J Immunol       Date:  2009-08-10       Impact factor: 5.422

3.  Postchallenge administration of brincidofovir protects healthy and immune-deficient mice reconstituted with limited numbers of T cells from lethal challenge with IHD-J-Luc vaccinia virus.

Authors:  Marina Zaitseva; Kevin Tyler McCullough; Stephanie Cruz; Antonia Thomas; Claudia G Diaz; Laurie Keilholz; Irma M Grossi; Lawrence C Trost; Hana Golding
Journal:  J Virol       Date:  2015-01-14       Impact factor: 5.103

4.  LC16m8, a highly attenuated vaccinia virus vaccine lacking expression of the membrane protein B5R, protects monkeys from monkeypox.

Authors:  Masayuki Saijo; Yasushi Ami; Yuriko Suzaki; Noriyo Nagata; Naoko Iwata; Hideki Hasegawa; Momoko Ogata; Shuetsu Fukushi; Tetsuya Mizutani; Tetsutaro Sata; Takeshi Kurata; Ichiro Kurane; Shigeru Morikawa
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Evaluating the orthopoxvirus type I interferon-binding molecule as a vaccine target in the vaccinia virus intranasal murine challenge model.

Authors:  Joseph W Golden; Jay W Hooper
Journal:  Clin Vaccine Immunol       Date:  2010-09-15

Review 6.  Countermeasures and vaccination against terrorism using smallpox: pre-event and post-event smallpox vaccination and its contraindications.

Authors:  Hajime Sato
Journal:  Environ Health Prev Med       Date:  2010-12-21       Impact factor: 3.674

7.  Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Authors:  Jay W Hooper; Anthony M Ferro; Joseph W Golden; Peter Silvera; Jeanne Dudek; Kim Alterson; Max Custer; Bryan Rivers; John Morris; Gary Owens; Jonathan F Smith; Kurt I Kamrud
Journal:  Vaccine       Date:  2009-10-13       Impact factor: 3.641

8.  Direct TLR2 signaling is critical for NK cell activation and function in response to vaccinia viral infection.

Authors:  Jennifer Martinez; Xiaopei Huang; Yiping Yang
Journal:  PLoS Pathog       Date:  2010-03-12       Impact factor: 6.823

9.  Safety mechanism assisted by the repressor of tetracycline (SMART) vaccinia virus vectors for vaccines and therapeutics.

Authors:  Patricia Grigg; Allison Titong; Leslie A Jones; Tilahun D Yilma; Paulo H Verardi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-29       Impact factor: 11.205

10.  Evaluation of smallpox vaccines using variola neutralization.

Authors:  Inger K Damon; Whitni B Davidson; Christine M Hughes; Victoria A Olson; Scott K Smith; Robert C Holman; Sharon E Frey; Frances Newman; Robert B Belshe; Lihan Yan; Kevin Karem
Journal:  J Gen Virol       Date:  2009-04-01       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.